The mission of the Survey Methods Core (SMC) facility is to assist Moffitt Cancer Center members with the design, implementation, and execution of research involving survey methods. Services provided by the SMC include consultations on research design, methods, and implementation, as well as the production and processing of scannable, web-based, and Computer Assisted Telephone Interviewing (CATI) surveys. Also offered are consultations about qualitative methods, including interviews, focus groups, and cognitive debriefing. The core has grown significantly since 2006. In addition to increasing and enhancing the range of services, the Core has added technical staff and expanded its physical space. The Core has more than doubled its space and now has four computer workstations in 300 square feet of space, as well as 300 square feet in a private CATI lab with four telephone interviewing stations. Currently there are three full-time positions and one part-time interviewer position. Since its inception, the SMC has implemented a working chargeback structure, increased its technical staff, and enhanced its menu of services. The Core's user base has been extended to include members from the Experimental Therapeutics and Molecular Oncology and Drug Discovery programs as well as those from the Health Outcomes and Behavior and Cancer Epidemiology. The Core requests CCSG Support of $83,457 which is 48% of its current operational budget. Over 84% of usage is by Moffitt members and peer-reviewed.
Survey methods are vital tools in cancer prevention, detection, and control research and are increasingly useful in clinical investigations of new cancer therapies. The data collection process, particularly for large-scale studies and studies using multiple sites, can be time consuming;however, services provided by the SMC have streamlined the process.
|Eroglu, Zeynep; Zaretsky, Jesse M; Hu-Lieskovan, Siwen et al. (2018) High response rate to PD-1 blockade in desmoplastic melanomas. Nature 553:347-350|
|Lu, Yingchang; Beeghly-Fadiel, Alicia; Wu, Lang et al. (2018) A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Res 78:5419-5430|
|Phadke, Manali; Remsing Rix, Lily L; Smalley, Inna et al. (2018) Dabrafenib inhibits the growth of BRAF-WT cancers through CDK16 and NEK9 inhibition. Mol Oncol 12:74-88|
|Kasting, Monica L; Christy, Shannon M; Sutton, Steven K et al. (2018) Florida physicians' reported use of AFIX-based strategies for human papillomavirus vaccination. Prev Med 116:143-149|
|Jiang, Kun; Neill, Kevin; Cowden, Daniel et al. (2018) Expression of CAS/CSE1L, the Cellular Apoptosis Susceptibility Protein, Correlates With Neoplastic Progression in Barrett's Esophagus. Appl Immunohistochem Mol Morphol 26:552-556|
|Park, Jae H; Rivière, Isabelle; Gonen, Mithat et al. (2018) Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia. N Engl J Med 378:449-459|
|Poort, Hanneke; Meade, Cathy D; Knoop, Hans et al. (2018) Adapting an Evidence-Based Intervention to Address Targeted Therapy-Related Fatigue in Chronic Myeloid Leukemia Patients. Cancer Nurs 41:E28-E37|
|Pamnani, Shitaldas J; Sudenga, Staci L; Rollison, Dana E et al. (2018) Recurrence of Genital Infections With 9 Human Papillomavirus (HPV) Vaccine Types (6, 11, 16, 18, 31, 33, 45, 52, and 58) Among Men in the HPV Infection in Men (HIM) Study. J Infect Dis 218:1219-1227|
|Dai, Juncheng; Li, Zhihua; Amos, Christopher I et al. (2018) Systematic analyses of regulatory variants in DNase I hypersensitive sites identified two novel lung cancer susceptibility loci. Carcinogenesis :|
|Cherezov, Dmitry; Hawkins, Samuel H; Goldgof, Dmitry B et al. (2018) Delta radiomic features improve prediction for lung cancer incidence: A nested case-control analysis of the National Lung Screening Trial. Cancer Med 7:6340-6356|
Showing the most recent 10 out of 1254 publications